Floatz logo

6 assets in Synchronous Bilateral Breast Carcinoma

Therapeutic assets addressing Synchronous Bilateral Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Anastrozole
Synchronous Bilateral Breast Carcinoma
National Cancer Institute (NCI)P3B (60)
Exemestane
Synchronous Bilateral Breast Carcinoma
National Cancer Institute (NCI)P3B (60)
Letrozole
Synchronous Bilateral Breast Carcinoma
National Cancer Institute (NCI)P3B (60)
Tamoxifen
Synchronous Bilateral Breast Carcinoma
National Cancer Institute (NCI)P3B (60)
Trastuzumab Emtansine
Synchronous Bilateral Breast Carcinoma
Alliance for Clinical Trials in OncologyP3B (60)
Tucatinib
Synchronous Bilateral Breast Carcinoma
Alliance for Clinical Trials in OncologyP3B (60)